Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 17/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 17/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977621 | 0.89 | CYP11B1 (0.53) | CYP11B2CYP11B1CYP3A4GRM2 | |
| SCHEMBL3975895 | 0.88 | CYP11B2 (0.53) | CYP11B2CYP11B1CYP3A4GRM2 | |
| SCHEMBL3975074 | 0.88 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL4088218 | 0.88 | CYP11B1 (0.47) | CYP11B2CYP11B1CYP3A4GRM2 | |
| SCHEMBL3981958 | 0.88 | CYP11B2 (0.57) | CYP11B2CYP11B1CYP3A4FNTAFNTB | |
| SCHEMBL4082693 | 0.85 | CYP11B2 (0.56) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL3977142 | 0.83 | CYP11B2 (0.41) | CYP11B2CYP11B1CYP3A4GRM2 | |
| SCHEMBL3976120 | 0.83 | CYP11B2 (0.42) | CYP11B2CYP11B1CYP3A4GRM2 | |
| SCHEMBL3980433 | 0.82 | CYP11B1 (0.41) | CYP11B2CYP11B1CYP3A4 | |
| SCHEMBL4094875 | 0.82 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP3A4FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008027284-A1 | FUSED IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY ALDOSTERONE SYNTHASE AND/OR 11-BETA-HYDROXYLASE AND/OR AROMATASE | NOVARTIS AG (CH) | 2008-03-06 | — | — | WO | disclosed |